article 3 months old

CSL’s FY26 Suggests The Downtrend Is Done

Australia | Aug 19 2026

This story features CSL LIMITED.
For more info SHARE ANALYSIS: CSL

The company is included in ASX20, ASX50, ASX100, ASX200, ASX300 and ALL-ORDS

CSL's FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades.

  • CSL’s FY26 result beat low expectations
  • Slowing declines in the second half from the first imply positive trends
  • More constructive commentary around Ig markets the highlight of FY27 guidance
  • The worst appears over, but most analysts remain cautious

By Greg Peel

CSL's FY26 market update suggests operations are stabilising

CSL’s FY26 market update suggests operations are stabilising

CSL Ltd’s ((CSL)) FY26 results proved better than expected, although expectations had been lowered heading into the announcement.

FY26 revenue of US$15.8bn was up 2% on FY25 and 3% ahead of consensus expectations. Underlying profit of US$3.0bn was down -3% on FY25 on higher tax, but 1% ahead of consensus.

A final dividend of US$1.62 took the total FY26 dividend to US$2.92, flat on FY25. The company also announced a $1.1bn share buyback for FY27.

Breaking it Down

In the primary Behring division, revenues were 2% ahead of consensus, though down -1% on FY25 in constant currency terms.

Immunoglobulin (Ig) revenue was flat in FY26 but –importantly– showed a material improvement in the second half, Ord Minnett notes, rising 7% year on year.

Similarly, albumin revenue declined -17% in FY26, but the decline moderated to -5% in the second half with encouraging signs that price declines in China, reflecting government cost containment measures, are slowing.

While pricing remains challenging, volume trends have stabilised and CSL continues to expand its hospital and retail footprint, Morgans notes.

Revenues in Seqirus were 2% ahead of consensus, albeit down -8% in constant currency terms on FY25, largely due to bird flu contracts in FY25 not being repeated.

Encouragingly for Ord Minnett, seasonal (human) flu vaccine revenues rose 4%, and management expects support from growth in new markets and a slower drop in US immunisation rates ahead.

Revenues in Vifor increased 3% in constant currency and were 3% ahead of consensus, as stronger kidney treatment sales offset competition-driven weakness in iron products.

Guidance

FY27 guidance is for revenue in constant currency terms to be flat on FY26, with underlying profit growth of 5%.

Guidance assumes mid-single-digit revenue growth in CSL Behring, and low-single-digit revenue growth in Seqirus, while Vifor revenues are expected to decline by -25% due to ongoing competition from generics in iron products.

Macquarie points out Seqirus and Vifor have a smaller impact on the group’s performance.

While FY27 guidance of 5% is largely underpinned by lower intellectual property amortisation and cost savings, and consequently has been viewed as low quality, RBC Capital thinks this is somewhat of a moot point, believing guidance is conservative.

While the guidance implies lacklustre growth in FY27, the more constructive commentary around Ig markets were what drove the shares higher, Ord Minnett suggests.

Management highlighted that underlying demand for Ig products was robust, US channel inventory was at more appropriate levels, and it expected Ig to grow in line with the market.

Morgans views this as an important change following the recent period of market share losses and inventory uncertainty.

An expected improvement in Behring’s gross margin, and slower rates of decline in China albumin pricing and US immunisation rates were also well received.

The FY27 outlook implies a stronger recovery in Behring sales (mid-single-digit) from a higher starting point, and a modest lift in gross margin offset by the larger (-25%) contraction in Vifor sales.

The cost savings program is ahead of plan and UBS notes 5% of savings in FY27 will be reinvested in growth opportunities.

It appears CSL does not need a material market share recovery to generate earnings growth, Morgans suggests, as long as Behring grows with the Ig market, transformation savings are delivered and newer products continue to scale.

The Response

CSL’s share price fell -69% between July 2024 and May this year. There followed a recovery, with the FY26 result release alone worth a 23% spike. 

The share price peaked during the early stages of the global covid pandemic at $342.75 and had subsequently largely trended sideways until the third quarter of 2024, after which it fell hard, and kept selling off.

While FY27 hardly looks exciting, positive trends (or less negative trends) appear to be emerging after a bleak couple of years.

While FY26 was another difficult year, Morgans views the latest result as providing greater confidence that the repeated earnings downgrades are coming to an end.

Morgans is one of three brokers monitored daily by FNArena covering CSL to retain a Buy or equivalent rating.

UBS sees the company now in transition back to sustainable growth.

Morgan Stanley (Overweight) sees the FY26 result and FY27 guidance, on balance, as highlighting incremental improvement within CSL Behring, the key driver of group earnings growth over the medium to longer term.

Morgan Stanley’s forecasts imply solid underlying profit growth, supplemented by an ongoing buyback program.

The other four covering brokers retain Hold or equivalent ratings.

Despite signs of stabilisation, Macquarie sees ongoing uncertainty across core business segments (Ig, albumin) and medium-term competitive risks (new Ig products, complement inhibitors, recombinant albumin).

While FY27 targets flat revenue growth, as Vifor remains a significant drag, the earnings trajectory is becoming increasingly skewed towards recovery, Morgans suggests, supported by stabilising plasma economics, cost-outs and improved commercial execution.

Citi agrees the worst seems past, but with a base-case forecast for similar growth for the mid-term, and given recent share price appreciation, Citi remains Neutral.

With the result not moving earnings forecasts much, and the shares trading close to the broker’s target price, Ord Minnett keeps a Hold recommendation.

While the result suggests the worst (by way of earnings declines) is in the rear-view mirror for CSL, Bell Potter finds it difficult to justify a greater premium than is now being attributed relative to global biopharma peers.

Bell Potter notes global biopharma peers currently trade on a median 14x PE with a median three-year revenue compound annual growth rate of 4.6%, compared to CSL’s 18x PE and 2% revenue CAGR.

The consensus target among the seven aforementioned brokers has risen to $162.31 from $132.84.

All three Buy-raters have price targets above the current share price of $163.48, targets set by the others are below today’s price.

See Stock Analysis on the website for more details.

There had been concerns that CSL’s Ig revenue growth had been tracking below peers for the last few periods, but RBC Capital expects CSL’s second half performance will alleviate the market’s growth concerns for the business.

While lifting its target to $148 from $108, RBC retains a Sector Perform rating.

Find out why FNArena subscribers like the service so much: “Your Feedback (Thank You)” – Warning this story contains unashamedly positive feedback on the service provided.

FNArena is proud about its track record and past achievements: Ten Years On

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

CHARTS

CSL

For more info SHARE ANALYSIS: CSL - CSL LIMITED

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.